Related Experiment Video
Updated: Jul 16, 2026
09:41
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
8.7K
Comprehensive evaluation of genetic and acquired thrombophilia markers for an individualized prediction of clinical
Irene Sánchez Prieto1, Isabel Gutiérrez Jomarrón2, Celia Martínez Vázquez2
1Hematology Department, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain. irenesprieto92@gmail.com.
Journal of Thrombosis and Thrombolysis
|April 27, 2024
Summary
This study identified key risk factors for venous thromboembolism (VTE) in lymphoma and multiple myeloma patients. Combining clinical data, biomarkers, and genetics can improve VTE risk prediction for these high-risk cancer patients.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Patients with lymphoma and multiple myeloma face a higher risk of venous thromboembolism (VTE).
- Accurate risk stratification and effective preventative measures require a comprehensive risk score accounting for the complex prothrombotic state in these patients.
Purpose of the Study:
- To identify thrombosis risk factors in lymphoma and multiple myeloma patients.
- To propose an improved risk prediction tool integrating clinical, thrombo-inflammatory, and genetic variables.
Main Methods:
- A prospective longitudinal study of 63 newly-diagnosed lymphoma and multiple myeloma patients.
- Follow-up for 1 year, analyzing VTE incidence, risk factors, and genetic markers (Thrombo inCode® test).
- Calculation of established risk scores (Khorana, ThroLy, IMPEDE VTE).
Main Results:
- VTE incidence was 9.5% (6/63) at a median follow-up of 9.1 months.
- Higher thrombosis risk was associated with ECOG performance status ≥2, prior immobility, and elevated Factor VIII levels.
- Trends indicated increased risk with Factor V Leiden, serpinA10 rs2232698, low protein S, elevated D-dimer, aggressive lymphoma, and dexamethasone treatment.
Conclusions:
- Accessible markers like ECOG status, immobility, Factor VIII, D-dimer, protein S activity, and dexamethasone treatment show promise for VTE risk prediction.
- Genetic variants (Factor V Leiden, serpinA10, Factor XIII) warrant further investigation for enhanced VTE risk assessment in these patient populations.
